I'm ‘Dr. Butthole' — beware this warning sign that could lead to a scary ‘silent disease'
That's a bummer!
Anal cancer is on the rise, particularly among white and Hispanic women over the age of 65. The lifetime risk of developing anal cancer is around 1 in 500, according to the American Cancer Society, which predicts about 11,000 new cases and 2,000 deaths this year.
Dr. Evan Goldstein, an NYC-based anal surgeon known colloquially as Dr. Butthole and 'the bottom whisperer,' cautions about a warning sign that can increase the risk of getting diagnosed with this 'silent disease.'
Advertisement
4 Dr. Evan Goldstein, an NYC-based anal surgeon, wrote 'Butt Seriously: The Definitive Guide to Anal Health, Pleasure and Everything In Between.'
Courtesy of Dr. Evan Goldstein
'Anal cancer stems from the HPV virus and, for many, from the development of anal warts,' Goldstein, founder and CEO of Bespoke Surgical and Future Method, told The Post.
About 90% of anal cancers are linked to infection with the human papillomavirus (HPV).
Advertisement
HPV is a group of over 200 related viruses primarily spread through skin-to-skin contact.
The Centers for Disease Control and Prevention estimates that 85% of people will get HPV at some point.
4 This man has a skin lesion from human papillomavirus. Untreated skin lesions caused by HPV can potentially progress to anal cancer.
Parilov – stock.adobe.com
Certain strains of HPV are known to cause anal warts — and these benign growths can be difficult to distinguish.
Advertisement
They may present as a single bump in the anal region or as a cluster that resembles cauliflower. Most are raised, but some are flat.
'Many think they are just skin tags and then find out it's anal warts from HPV,' said Goldstein, author of 'Butt Seriously: The Definitive Guide to Anal Health, Pleasure and Everything In Between.'
'They can be painful and itchy and lead to bleeding.'
Advertisement
Some patients don't have any symptoms and may not know they have anal warts.
Treatment includes topical medications, cryotherapy or surgical removal.
The body's immune system often clears HPV infections naturally, usually within a few years, but some persist.
4 Anal warts can be itchy and painful or not have any symptoms.
Wasan – stock.adobe.com
Chronic infections with certain high-risk types of HPV can cause changes in anal cells, potentially leading to precancerous lesions. If left untreated, they can progress to invasive anal cancer.
Symptoms of anal cancer include rectal bleeding, a lump near the anus, pain or pressure in the anal area, itching or discharge from the anus and changes in bathroom habits.
In the early stages, there may not be noticeable symptoms.
'The idea is to catch this early with early detection anal pap smears and full anoscopy (in and out visualization with a camera and high-resolution scope) with an appropriate anal practitioner,' Goldstein advised.
Advertisement
When found early, anal cancer is often highly treatable. Five-year survival rates after diagnosis hover around 64%.
4 Goldstein recommends seeing an anal specialist, especially if engaging in anal play, for internal and external evaluations and anal pap smears that can detect changes in the cells lining the anal canal.
theartofphoto – stock.adobe.com
Prevention is key. All teens should get Gardasil 9, a series of shots that can protect against certain types of HPV infections, Goldstein said.
Researchers suggest that the recent anal cancer surge in older women could be due to these women being beyond the age recommended for HPV inoculation when it became widely available in 2006.
Advertisement
Goldstein also recommends seeing an anal specialist, especially if engaging in anal play, for internal and external evaluations and anal pap smears that can detect changes in the cells lining the anal canal.
'The more we talk about [anal health] and standardize yearly evaluations, similar to gynecology appointments, the better all of us will be,' he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
What is thimerosal, the flu vaccine ingredient targeted by RFK Jr.?
Federal vaccine advisers installed by Health and Human Services Secretary Robert F. Kennedy Jr. voted Thursday to stop recommending influenza vaccines containing thimerosal, a preservative that has been long criticized by anti-vaccine activists. Scientists and public health authorities have deemed thimerosal safe, and the vast majority of flu shots don't have it. But the removal would probably make flu vaccines more expensive and harder to receive for some Americans, public health experts said. Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. Medical experts say the move is the latest by Kennedy, who was a longtime anti-vaccine activist before he joined the Trump administration, to chip away at vaccine policies. Here's what to know about thimerosal: - - - What is thimerosal? Thimerosal, which the Food and Drug Administration describes as a 'mercury-containing organic compound,' is used as a preservative in vaccines to stop microbial growth and prevent contamination. Since 2001, all childhood vaccines licensed and recommended in the United States have been thimerosal-free, with the exception of some multi-dose formulations of flu vaccines. When used in vaccines, it is metabolized into ethylmercury in the body, which is vastly different from methylmercury, which can be found in fish. The levels of ethylmercury in vaccines have been found to be safe, while high levels of methylmercury can cause childhood developmental damage, medical experts and the U.S. government says. 'There is a robust body of peer-reviewed, scientific studies conducted in the United States and countries around the world that support the safety of thimerosal-containing vaccines,' the FDA writes on its website. The Centers for Disease Control and Prevention posted a 17-page document online this week saying thimerosal was safe. That document was intended to be background material for members of the Advisory Committee on Immunization Practices before its meeting and vote, according to a federal health official familiar with the document. But it was posted on the ACIP website, and then removed Wednesday. 'This document by the CDC vaccine safety office did not go through the appropriate process to be posted,' an HHS spokesperson told The Washington Post. - - - Why is thimerosal controversial? In the 1990s, amid suspicion thimerosal could be a cause behind the rising rates of autism, the U.S. Public Health Service and the American Academy of Pediatrics recommended thimerosal be removed from vaccines out of an abundance of caution and to restore public confidence. By the early 2000s, thimerosal had been removed or reduced to trace amounts in most childhood vaccines, with manufacturers increasingly using single-dose vials that did not require preservatives. Several studies have shown that there is no link between thimerosal and autism. 'There is no evidence to suggest that the amount of [thimerosal] used in vaccines poses a health risk,' according to the World Health Organization, which says other medical groups in the U.S. and Europe hold the same views. After thimerosal was removed from most childhood vaccines, autism rates have continued to rise. - - - What is the impact of removing thimerosal? It would be limited. In the most recent flu season, 94 percent of all influenza vaccines administered in U.S. were thimerosal free, according to the CDC. The rate was even higher for shots administered through two major government vaccine programs. Multi-dose vials are easier to store and use for large vaccine fairs than the single-dose counterparts. They're also less expensive, reducing waste and requiring less space to store. Public health experts said medical facilities targeted at rural areas and safety net systems could face potential shortages if they remove those vaccines, although an FDA representative at the meeting said there would be enough supply to make up for the shortfall. - - - What has Kennedy said about thimerosal? Before the meeting on Tuesday, Kennedy decried the description of thimerosal as safe, writing on X that 'I leave it to the reader to speculate as to why CDC has not performed such studies in the intervening 24 years as it dosed hundreds of millions of American children and pregnant moms with mercury-laden flu shots.' On his social media post, he cited several studies he said supported his claims - and contradicted his own agencies. Medical experts told The Post that Kennedy was misstating the science. 'It's a way to overwhelm an audience who mostly WON'T click each one to find what they are looking for,' said Jessica Malaty Rivera, an infectious-disease epidemiologist, in a text. 'Second, there is zero evidence of his claims in any of those links.' In 2015, Kennedy edited a book titled 'Thimerosal: Let the Science Speak' in which he wrote 'the evidence of thimerosal's neurotoxicity is so overwhelming and the lack of any safety data so complete that anyone who is willing to read science and who believes in the capacity for scientific methods to determine empirical truths must conclude that thimerosal causes serious brain damage.' He also noted in his introduction that he 'assembled this book' to persuade the CDC to get rid of thimerosal in any vaccines. In a speaking appearance in April 2023 challenging coronavirus mandates, Kennedy pointed to his book, calling it 'definitive' proof that thimerosal 'is the cause of all these neurological injuries.' He went on a podcast later that year, where he talked more about thimerosal. 'This particular kind of vaccine, the multi-dose vial, is going to children, little children, it's destroying their brains,' Kennedy said in a July 2023 podcast appearance. 'You can accept that or not, I'm telling you that that's my belief, and I believe my belief is strongly grounded in science.' - - - Caitlin Gilbert and Lena H. Sun contributed to this report. Related Content Dynamite outside a synagogue: Civil rights stories imperiled by federal cuts In West Virginia, Medicaid is a lifeline. GOP cuts could devastate the state. 3-pound puppy left in trash is rescued, now thriving
Forbes
29 minutes ago
- Forbes
Systemic Vulnerabilities In US Healthcare: Emerging Solutions
Vlad Panin, CEO at iFrame, is a corporate lawyer, healthcare administration expert and scientist. The U.S. healthcare system—nearly a fifth of the nation's GDP—faces mounting financial and operational stress, with dramatic episodes like the 2024 Change Healthcare cyberattack exposing deep-rooted risks from centralization, fragmented cyber defenses and dependency on opaque, outsourced administrative processes. At the same time, I see a generational shift in artificial intelligence (AI) as creating an unprecedented opportunity: The accelerated verticalization of AI—"agent-first" applications trained for domain-specific workflows—which can allow the U.S. to reshore and reinvent medical revenue cycle management (RCM), helping restore trust, efficiency and resilience. From Centralization Crisis To AI Opportunity Change Healthcare, processing $2 trillion in annual claims and touching one-third of U.S. medical records, became a single point of catastrophic failure when a ransomware attack in early 2024 paralyzed claims and cash flow for hospitals nationwide—impacting 94% of hospitals financially, with 60% losing over $1 million per day. The root cause was a basic mistake: The failure to implement multi-factor authentication—compounded by the complexities of integrating legacy acquisitions. Small and medium-sized providers (SMBs) were hit hardest, with 80% suffering revenue loss and over half using personal funds to stay afloat. Meanwhile, a parallel crisis snowballed: Major insurers' use of proprietary AI algorithms, like UHG's nH Predict and Cigna's PxDx, drove record claims denials and lawsuits. Some algorithms were revealed to have high error rates—over 90% of nH Predict-based denials reversed upon appeal with complaints centered on a lack of transparency, lack of clinical review and a persistent sense that AI was being wielded as a blunt instrument to cut costs and compress provider margins. CMS and several states have now banned sole reliance on AI for claim determinations, ushering in a new regulatory era. AI Not Just Inevitable But Imminent And Vertical What's fueling the renewed optimism is not just AI's raw technical horsepower, but the abrupt market readiness for "verticalized" solutions—deeply embedded, domain-specific agents. AI is here, and its impact is accelerating. The necessary conditions are in place: computational power, broad access to distribution channels, a growing pool of skilled talent and rising global demand. What's particularly transformative is the speed at which new innovations are now reaching scale. While the cloud transition took years, AI achieved global awareness and trial almost overnight, and ChatGPT had hundreds of millions of users in months. Most importantly for healthcare, analysis from Sequoia "suggests the greatest value will accrue at the application layer." This means vertically integrated, workflow-specific AI agents—fine-tuned for specialty domains—will capture the largest profit pools and create the deepest competitive moats. Unlike generic tools, these agents can be co-pilots or autopilots for domain-specific work, such as revenue cycle management or prior authorization in healthcare. Sequoia has cited stunning user engagement growth in AI-native apps, especially in high-trust, regulated industries like healthcare. Startups like Open Evidence in diagnostics are already outperforming generalist models, while vertical agents in security and DevOps began outperforming top humans in 2024. US-Based, AI-Augmented Medical Coding The immediate implication for U.S. healthcare administration is profound. The historical justification for offshoring medical coding and RCM—lower labor costs—is being upended by vertical AI's ability to process claims far faster, more accurately and securely within U.S. borders. The human-in-the-loop paradigm—AI as supercharged analyst, certified coder as reviewer/arbiter—offers providers both scale and compliance. Innovation is moving in tandem with this shift. For example, AI Medical Coder Training Center now offers certified programs that guarantee job allocations for AI-upskilled coders, ensuring that the promise of AI does not displace skilled U.S. labor. Overall, it's important we focus on catalyzing jobs with larger compensation, increased regulatory compliance and higher trust. With government agencies and regulators implementing new cybersecurity and data localization standards—including mandatory multi-factor authentication, regular audits, and scrutiny of offshore PHI processing—the business case for reshoring healthcare administration is now both statutory and economic fact. From Missed Opportunity To Strategic Advantage Why act now? The physics of technology distribution has fundamentally changed: "Nature hates a vacuum," as Sequoia's leadership notes, and AI adoption is filling industry gaps at dizzying speed. The market is experiencing a "tremendous sucking sound" for domain-specific AI, as existing macro headwinds (tariffs, offshore volatility, rising cyber-attacks) pale in comparison to the relentless pull of scalable, value-creating automation. But not all AI-driven revenue is built to last. Savvy operators are beginning to distinguish between short-term curiosity spend and deeper, more sustainable value. The real movement lies in technology that drives lasting changes in behavior—tools that integrate into core workflows, reshape how people work and earn the trust of their users. In healthcare, especially, trust is emerging as the true differentiator. It's no longer enough for an AI tool to perform well; customers need to believe their data is secure and that the technology won't compromise their care or privacy. Building For The Next Wave Looking ahead, healthcare's reinvention will require navigating new challenges like persistent agent memory (so agents remember institutional rules and patient context), seamless communication protocols for interoperability and zero-trust security frameworks given the impossibility of face-to-face verification. As "agent swarms" and the "agent economy" emerge—software agents negotiating, transacting and collaborating with and for human teams—vertical healthcare agents will become a critical locus of value, with the most credible actors being those who combine vertical expertise, technical excellence and ironclad governance. The winners will be those organizations that vertically integrate AI with real human oversight, U.S.-based certification, and cross-system trust, turning the weaknesses of centralization and opacity into strengths of agility, transparency and resilience. A Call To Action For US Healthcare Stakeholders Now is the critical window for U.S. healthcare payers and providers to leap ahead: Reshore RCM with vertical, AI-augmented applications; invest in certified, U.S.-based talent; demand transparent, audit-ready technology; and build networks of trust that give SMBs and enterprises alike a fighting chance. As new federal and state regulations favor local data and AI with human oversight, there has never been a better—or more urgent—moment to make the U.S. the global standard for secure, resilient, and equitable healthcare administration in the era of agentic AI. Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?
Medscape
33 minutes ago
- Medscape
New Guidance on the Use of Unproven Neurologic Therapeutics
A new position statement outlining guiding principles for navigating the use of unproven therapies for neurologic conditions that lack approval from the FDA or robust scientific evidence has been released by the American Academy of Neurology (AAN). The statement is intended to support informed conversations between clinicians, patients, and policymakers about emerging or unproven treatments. While it includes examples of such therapies, the document stops short of offering clinical recommendations. The use of emerging neurologic therapies not yet supported by science has been 'an ongoing concern,' with patients often asking providers about these therapies, the statement's lead author Larry B. Goldstein, MD, professor and chair of the Department of Neurology and associate dean for Clinical Research, University of Kentucky, Lexington, Kentucky, told Medscape Medical News. Developed in response to requests from AAN members seeking guidance on emerging therapeutics, the statement outlines guiding principles to support clinical and policy discussions. It was published online on June 25 in Neurology. Lack of FDA-Approved Options Many neurologic diseases have no available FDA-approved therapeutic options and no, or limited, evidence-based treatments. However, many potential treatments, both synthetic and naturally occurring, may be in varying stages of expert evaluation for neurologic conditions. Psychedelics have emerged as potential therapies for pain disorders such as cluster headache, as well as psychiatric conditions including major depression, posttraumatic stress disorder (PTSD), generalized anxiety, and substance use disorders. However, data on psychedelics' risks and benefits for these indications are limited. The AAN committee cites the example of midomafetamine combined with psychotherapy for the treatment of PTSD. Although this approach has generated interest, an FDA advisory committee recently recommended against its approval, citing significant methodological flaws in the supporting studies and advising the FDA to reject the Investigational New Drug Application. 'This illustrative example highlights the need for rigorous, placebo-controlled, double-blind trials to adequately test the effectiveness of these therapies while exhaustively documenting adverse events to characterize patient safety issues,' the statement's authors noted. The AAN supports the FDA-accelerated review of novel therapeutics for neurologic conditions 'when this process is appropriate,' said Goldstein. Off-Label Use The statement also addresses the expanded use of therapies beyond their original FDA-approved indications — for example, the off-label use of alteplase for thrombolysis in ischemic stroke patients treated 3-4.5 hours after they were last known to be well, as well as the use of tenecteplase in select cases of acute ischemic stroke. Goldstein noted that these examples reflect issues commonly encountered in hospitals nationwide. 'The AAN supports the off-label use of FDA-approved therapies in settings in which the high-quality evidence indicates that the benefit of the therapy outweighs the risks with shared decision-making between the patient and physician in the model of informed consent,' the statement authors noted. Another example is natalizumab, a humanized IgG4κ monoclonal antibody approved for the treatment of relapsing-remitting multiple sclerosis (MS). The drug was initially withdrawn from the market following reports of progressive multifocal leukoencephalopathy. However, it was later reintroduced, as some patients with MS have no alternative therapies to effectively manage their disease. Physician-patient discussions about unproven therapies might include situations where patients are considering their 'Right to Try.' Signed into law in 2018, the Right to Try Act allows individuals with a terminal illness who have tried all approved treatments and who are unable to participate in a clinical trial to receive an experimental treatment. The statement also addresses the issue of adverse events reported after FDA approval. For example, the statin cerivastatin was approved for cholesterol reduction but was withdrawn from clinical use following reports of deaths and hospitalizations. These cases, said Goldstein, illustrate the complexity of this issue. 'It's particularly challenging because healthcare providers must be constantly aware of new data that may become available as therapeutics enter general use after FDA approval,' said Goldstein. In cases where a therapy is approved but carries significant risks or an incomplete adverse event profile, the statement advises that the AAN should generally refrain from taking a definitive position until further review by the FDA is completed. Unproven 'Treatments' The authors also address the use of therapeutics with limited or no supporting data, many of which have been popularized on social media, to treat or prevent conditions such as dementia. Such use not only exposes patients to unknown risks but may also discourage them from pursuing evidence-based treatments or participating in clinical trials that could offer potential benefits, Goldstein noted. When seeing patients, healthcare providers should discuss potential participation in a relevant trial and ask more detailed questions about the use of unproven therapies, he said. 'Physicians should routinely not only confirm their patient's prescribed medications but also ask about any other substances they may be using. Some, including certain supplements, may have potential toxicities or interactions with prescribed medications.' Discussions between neurologists and patients about unproven therapies are becoming increasingly relevant. 'In the current climate of unfiltered, at times incorrect or misinterpreted information, having a trustworthy source of fact-based advice is critically important,' said Goldstein. 'The neurologist brings particular expertise and training related to neurological disorders and what is known about the risks and benefits of potential treatments to help inform patient decisions,' he added. The AAN policy statement offers 'a framework' to guide neurologists in their role as patient advocates, Goldstein added. Although it does not address specific treatments, it does provide a structure for conversations with patients, said Goldstein.
